Results 1 to 10 of about 2,943 (80)
抗体药物偶联物治疗转移性去势抵抗性前列腺癌研究进展 [PDF]
浙江大学学报. 医学版转移性去势抵抗性前列腺癌（mCRPC）患者因肿瘤异质性和耐药性预后不佳，抗体药物偶联物（ADC）治疗mCRPC部分临床试验中已展现出抗肿瘤活性及较好的安全性。在靶向前列腺特异性膜抗原（PSMA）的ADC中，相较于早期ADC如MLN2704、PSMA-ADC、MEDI3726，ARX517安全性更优，前列腺特异性抗原下降更显著。在靶向B7-H3的ADC中，MGC018和DB-1311也展现出抗肿瘤活性。靶向前列腺六跨膜上皮抗原（STEAP）1的DSTP3086S、靶向滋养层细胞表面抗原（TROP ...
徐 嘉程 +5 more
doaj +2 more sources
前列腺特异性膜抗原基因片段在酿酒酵母中的诱导表达及意义 [PDF]
Zhongshan Daxue xuebao. Yixue kexue ban, 2005 【目的】分析前列腺特异性膜抗原(PSMA)基因片段在酿酒酵母中的诱导表达情况，以便进一步探讨重组人PSMA的免疫活性并完成抗前列腺癌PSMA蛋白疫苗的制备。【方法】应用基因重组技术将人PSMAcDNA序列克隆入酿酒酵母穿梭诱导表达载体pYES2／NT，构建重组酵母真核表达质粒pYES2／NT-PSMA，转化酿酒酵母菌株INVSc1，尿嘧啶筛选出阳性克隆转化子，经半乳糖诱导表达后进行菌体全蛋白的Western blot检测。【结果】成功构建了PSMA的酵母真核表达重组子pYES2／NT-PSMA ...
陈贤憬 +4 more
doaj +2 more sources
Zhongshan Daxue xuebao. Yixue kexue ban锕-225（225Ac）具有高传能线密度、适宜的半衰期、短粒子射程和良好的配位能力等特性，是很有医用前景的α核素之一，在肿瘤的靶向放射性核素治疗中具有重要的研究价值。本文简要介绍了225Ac的物理和化学特性以及常用螯合剂（前列腺特异性膜抗原、奥曲肽、纳米载体等），围绕着以多肽或小分子为靶向分子、以单克隆抗体或蛋白为靶向分子和基于纳米载体的TAT药物，综述了225Ac标记的靶向药物在肿瘤中的应用和纳米材料对225Ac衰变子体的保留作用，分析其应用于治疗的价值，总结了225Ac标记方法和适宜螯合剂的选择 ...
王立琴, 柳江燕
doaj +2 more sources
前列腺特异性膜抗原新型剪接变异体PSM-E 在外周血的定量表达
Zhongshan Daxue xuebao. Yixue kexue ban, 2009 【目的】 检测分析前列腺特异性膜抗原(PSMA)及其新型剪接变异体(PSM-E)在前列腺癌(PCA)及良性前列腺增生(BPH)患者外周血中的表达,探讨其意义65377; 【方法】 通过实时荧光定量PCR方法对PSM-E65380;PSMA在前列腺癌(53例)和前列腺增生(79例)两组患者外周血中定量表达,分析其差异65377; 【结果】 PSM-E相对表达量在PCA组(-8.22 ± 0.32)高于BPH组(-9.99 ± 0.41),P < 0.001;PSMA相对表达量在PCA组(-12.51 ...
doaj +1 more source
Value of 18F-PSMA PET/MRI for early diagnosis of recurrence and metastasis in prostate cancer patients after radical prostatectomy [PDF]
, 2023 Objective: To investigate the value and significance of 18F-prostate-specific membrane antigen (18F-PSMA)-1007 PET/MR for early diagnosis of recurrence and metastasis in prostate cancer patients after radical prostatectomy (RP).
ZHOU Yilei, ZHANG Miao, GUO Rui, ZHOU Jinxin, LI Biao, LI Xiang
core +1 more source
Advances in basic research, clinical diagnosis and treatment of prostate cancer in 2022 [PDF]
, 2023 About 40%-70% of newly diagnosed prostate cancer patients in China are in the stage of metastatic disease, and the spatio-temporal heterogeneity of the occurrence and development of prostate cancer and the unique metastasis pattern make it difficult to ...
PAN Jian, ZHU Yao, DAI Bo, YE Dingwei
core +1 more source
Current status and treatment direction of the immune microenvironment of castration-resistant prostate cancer [PDF]
, 2023 With the rapid development of cancer immunology, more and more research focuses on the role of immune cells and signaling molecules in the tumor microenvironment. Prostate cancer is the second most common malignant tumor in men globally.
YANG Wenbo, ZHANG Bin, WU Jiahui, CUI Jie
core +1 more source
Role of 18F-MD-PSMA PET/CT in initial stage of intermediate and high risk prostate cancer [PDF]
, 2023 Objective·To evaluate the role of 18F-MD-PSMA PET/CT in the initial stage of patients with moderate and high risk prostate cancer (PCa).Methods·A total of 67 patients with moderate and high risk PCa who were treated in Xinhua Hospital, Shanghai Jiao Tong
CAI Lisheng +7 more
core +1 more source
Expert consensus on perioperative comprehensive treatment for high risk prostate cancer (2023 edition) [PDF]
, 2023 The incidence rate of prostate cancer is showing an upward trend year by year, gradually becoming an important disease affecting the health of middle-aged and elderly men.
Society of Male Reproductive System Oncology, China Anti-Cancer Association
core +1 more source
血清外泌体ERG、PSMA在前列腺癌患者中的表达及其预后评估价值
Zhongguo shiyan zhenduanxue, 2021 目的探讨血清外泌体ETS相关基因(ERG)、前列腺特异性膜抗原(PSMA)在前列腺癌(PCa)患者中的表达及其预后评估价值。方法选取2015年7月-2019年7月期间成都上锦南府医院收治的105例PCa患者为癌症组,100例良性前列腺增生患者为疾病组,同期体检的95例健康者为健康组;比较各组间血清外泌体ERG、PSMA的表达水平;根据危险因素分级将PCa患者分成低、中、高危险级别,比较各组PCa患者血清中ERG以及PSMA的表达水平;所有患者均获得1年随访,根据随访结果将患者分为存活组和死亡组 ...
姜庆
doaj